EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Cardiovascular Outcomes in a SELECT ‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Viveca Ritsinger iD, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K Svensson, Anna Norhammar iD

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8057-8071

DOI: 10.1111/dom.70899 ↗

At a glance

Journal article in Diabetes, Obesity and Metabolism, published online on 2026-06-16. Written by Viveca Ritsinger and 5 co-authors. Institution: Division of Cardiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden. Major MEDLINE topics: Obesity, Cardiovascular Diseases, Glucagon-Like Peptides. 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: Uppsala Universitet, Novo Nordisk Scandinavia AB, Department of Research and Development, Region Kronoberg.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised. We therefore aimed to (1) assess real‐world cardiovascular outcomes in a SELECT‐like cohort with obesity, (2) compare them to the general population and a broader population of individuals with obesity and (3) evaluate the cardiovascular preventive potential of semaglutide in this SELECT‐like cohort with obesity.

Methods

We used healthcare registries and electronic health records from three Swedish regions (2013–2023), covering ~40% of the national population, to identify individuals aged ≥ 45 years with obesity (body mass index [BMI] ≥ 30 kg/m 2 ) and established CVD but without diabetes, in alignment with the SELECT trial criteria. Cardiovascular outcomes in this SELECT‐like obesity cohort were compared with matched individuals from the general population as well as with a broader population of individuals with obesity, irrespective of CVD status or other comorbid conditions. To estimate the number needed to treat (NNT), the relative treatment effect of semaglutide observed in the SELECT trial was applied to the absolute risks identified in the SELECT‐like obesity cohort .

Results

The SELECT‐like obesity cohort ( n = 9652) had a mean (SD) age of 68.4 (11.3) years, a mean BMI of 33.1 kg/m 2 (SD 3.5) and 57.9% were men. Most had a history of myocardial infarction (48.1%) or stroke (41.7%). Over a mean (SD) follow‐up of 5.4 (3.2) years, MACE occurred in 21.7%. Compared with the SELECT trial, this real‐world population had a higher mean age, had a higher proportion of females, and more often had a prior stroke. Applying the estimated effect of semaglutide from the SELECT trial, the NNT to prevent one MACE was 35 (95% CI, 24–66). Compared with the General population cohort ( n = 48 260), the SELECT‐like obesity cohort had a higher burden of cardiovascular and obesity‐related comorbidities and an increased risk of adverse cardiovascular outcomes, including MACE (HR 2.3 [2.2–2.4]) and heart failure (HR 2.7 [2.5–2.9]).

Conclusion

In a real‐world setting, despite the use of extensive preventive medications, individuals with obesity and CVD had a higher risk of adverse cardiovascular outcomes and mortality compared with the SELECT trial as well as the general population. These findings highlight the substantial disease burden and the need for improved secondary CVD prevention strategies.

Subjects

MeSH terms (MEDLINE)

ObesityCardiovascular DiseasesGlucagon-Like PeptidesHumansMaleSemaglutideFemaleSwedenMiddle AgedAgedCohort StudiesDatabases, FactualRegistriesAnti-Obesity AgentsBody Mass Index

Author keywords

antiobesity drugcardiovascular diseasedisease preventionobservational studypopulation studyreal‐world evidence

Substances

SemaglutideGlucagon-Like PeptidesAnti-Obesity Agents

Authors and institutions

  • Division of Cardiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
  • Department of Research and Development, Region Kronoberg, Växjö, Sweden.
  • Novo Nordisk Scandinavia AB, Malmö, Sweden.
  • Sence Research AB, Uppsala, Sweden.
  • Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden.
  • Uppsala Clinical Research Centre, Uppsala, Sweden.

ORCID profiles: Viveca Ritsinger, Anna Norhammar

Funding

  • Uppsala Universitet
  • Novo Nordisk Scandinavia AB
  • Department of Research and Development, Region Kronoberg
  • The Swedish Heart-Lung Foundation
  • ALF Medicine, Region Stockholm

Cite

APA

Ritsinger, V., Fagerström, J., Nero, H., Cars, T., Svensson, M. K., & Norhammar, A. (2026). Cardiovascular Outcomes in a SELECT ‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database. Diabetes, Obesity and Metabolism, 28(9), 8057-8071. https://doi.org/10.1111/dom.70899

Vancouver

Ritsinger V, Fagerström J, Nero H, Cars T, Svensson MK, Norhammar A. Cardiovascular Outcomes in a SELECT ‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database. Diabetes, Obesity and Metabolism. 2026;28(9):8057-8071. doi:10.1111/dom.70899

BibTeX
@article{Ritsinger2026,
  author = {Ritsinger, Viveca and Fagerström, Josefine and Nero, Håkan and Cars, Thomas and Svensson, Maria K and Norhammar, Anna},
  title = {Cardiovascular Outcomes in a SELECT ‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8057--8071},
  doi = {10.1111/dom.70899}
}
Start for free →